Proteome Systems Drops Intended Prostate Dx
 
Proteome Systems is abandoning its efforts to create a semen-based diagnostic test for prostate cancer, the Australian company announced this week.
 
The decision was after results of a proof-of-concept study “demonstrated the project did not satisfy internal assessment hurdles,” Proteome Systems said in a statement.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.